# Successful Treatment of Extragenital Lichen Sclerosus With Roflumilast 0.3% Cream: A Report of Two Cases

## TL;DR

Two patients with extragenital lichen sclerosus showed improvement using roflumilast 0.3% cream, suggesting it could be an effective treatment option.

## Contribution

This paper reports the first cases of successful treatment of extragenital lichen sclerosus with roflumilast cream.

## Key findings

- Two patients with extragenital lichen sclerosus showed clinical improvement after using roflumilast 0.3% cream.
- Symptomatic improvement was observed as early as one month after starting treatment.

## Abstract

Extragenital lichen sclerosus (EGLS) is often resistant to first-line ultrapotent corticosteroids, with few steroid-sparing options available. Topical roflumilast has been approved by the US Food and Drug Administration (FDA) for an expanding number of indications in dermatology, including plaque psoriasis, atopic dermatitis, and, most recently, seborrheic dermatitis. We present two cases of symptomatic EGLS, who both demonstrated clinical improvement using roflumilast 0.3% cream as early as one month of follow-up.